On Monday shares of Connecture, Inc. (NASDAQ:CNXR) closed at $10.68. Company’s EPS growth for next 5 years is recorded as 22.50%. Connecture, Inc. (NASDAQ:CNXR) announced that Grant Hoffman, the company’s vice president and general manager of private exchanges, will participate in a panel discussion at the Institute for HealthCare Consumerism’s (IHC) Private Exchange FORUM. Taking place in Dallas, Texas from March 31 – April 1, the event will provide employers, brokers, advisors and insurers with an opportunity to gain valuable insights on private exchanges and relevant topics and trends.
Amicus Therapeutics, Inc. (NASDAQ:FOLD) in last trading activity increased 0.09% to close at $10.97. Company weekly performance is -4.28% while its quarterly performance stands at 34.11%. Amicus Therapeutics, Inc. (NASDAQ:FOLD) is -16.89% away from its 52 week high. On March 20, it was reported that, Amicus Therapeutics, Inc. (NASDAQ:FOLD) plans to submit for accelerated approval of its treatment experiments on a drug, Migalastat, which is a monotherapy drug for patients suffering from Fabry disease.
On last trading day Hormel Foods Corporation (NYSE:HRL) increased 0.17% to close at $57.36. Its volatility for the week is 1.62% while volatility for the month is 1.59%. HRL’s sales growth for past 5 years was 7.40% and its EPS growth for past 5 years was 11.90%. Hormel Foods Corporation (NYSE:HRL) monthly performance is -1.97%. On March 24, Hormel Foods Corporation (NYSE:HRL) announced the retirement of Julie H. Craven, vice president of corporate communications, and Joe C. Swedberg, vice president of legislative affairs. As a result, Wendy A. Watkins, global vice president of corporate communications at Delaware North Companies, will assume the position of vice president of corporate communications at Hormel Foods. Jeffrey A. Grev, director of legislative affairs, will advance to the position of vice president of legislative affairs.
On Monday shares of Merck & Co. Inc. (NYSE:MRK) closed at $58.34. Company’s sales growth for last 5 years was 9.00% and EPS growth for next 5 years is recorded as 4.79%. Merck & Co. (NYSE:MRK)‘s stock had its “hold” rating reaffirmed by Zacks in a note issued to investors on Friday. They currently have a $66.00 price target on the stock. Zacks‘s price objective would suggest a potential upside of 14.29% from the stock’s previous close.
Eli Lilly and Company (NYSE:LLY) in last trading activity increased 0.39% to close at $73.87. Company weekly performance is -3.26% while its quarterly performance stands at 5.69%. Eli Lilly and Company (NYSE:LLY) is -4.63% away from its 52 week high. On March 27, it was reported that, Eli Lilly and Company (NYSE:LLY) and Innovent Biologics, Inc. have entered a drug development collaboration, one of the largest such agreements in China to date. Under the terms of the agreement, Lilly and Innovent will collaborate to support the development and potential commercialization of at least three cancer treatments over the next decade.